Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Convertible Debt (2017 - 2025)

Guided Therapeutics' Convertible Debt history spans 12 years, with the latest figure at $35000.0 for Q1 2025.

  • For Q1 2025, Convertible Debt fell 96.9% year-over-year to $35000.0; the TTM value through Mar 2025 reached $35000.0, down 96.9%, while the annual FY2024 figure was $14000.0, N/A changed from the prior year.
  • Convertible Debt for Q1 2025 was $35000.0 at Guided Therapeutics, up from $14000.0 in the prior quarter.
  • Across five years, Convertible Debt topped out at $1.1 million in Q1 2024 and bottomed at -$185000.0 in Q1 2021.
  • The 5-year median for Convertible Debt is $852000.0 (2021), against an average of $592750.0.
  • The largest annual shift saw Convertible Debt tumbled 281.37% in 2021 before it surged 509.94% in 2023.
  • A 5-year view of Convertible Debt shows it stood at $820000.0 in 2021, then grew by 27.56% to $1.0 million in 2022, then fell by 6.12% to $982000.0 in 2023, then tumbled by 98.57% to $14000.0 in 2024, then surged by 150.0% to $35000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Convertible Debt are $35000.0 (Q1 2025), $14000.0 (Q4 2024), and $1.1 million (Q3 2024).